AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$2.55 USD
-0.01 (-0.39%)
Updated Jul 31, 2024 04:00 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANTX 2.55 -0.01(-0.39%)
Will ANTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANTX
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
ANTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
Other News for ANTX
Strong Buy on AN2 Therapeutics: Anticipating Positive Phase 2 Outcomes and Robust Financial Position
12 Health Care Stocks Moving In Friday's After-Market Session
Maintain Market Perform: Balancing Potential and Uncertainty in AN2 Therapeutics’ Drug Development
AN2 Therapeutics price target lowered by $5 at Evercore ISI, here's why
AN2 Therapeutics reports Q1 results